glp-1 drugs and alzheimer's GLP-1R agonists protect against disease by rewiring energy regulation GLP-1 Drugs and Brain Health:

However, the potential for delaying or preventing the progression of T2DM in patients treated with GIP and GLP-1 remains uncertain, as there is currently no definitive evidence from human studies demonstrating that enhanced incretin activity directly affects -cell mass or alters the progressive loss of insulin secretory capacity in humans

P5 is more effective at controlling chronic hyperglycaemia To determine whether chronic treatment with the GLP-1R G-protein-biased agonist can improve hyperglycaemia, ob/ob mice were treated daily with 10 g kg 1 of P5 or Ex4 for 3 weeks

compared the risk of aspiration among GLP-1 RA users to SGL-2i users and concluded that the weighted risk of the two groups was 4.15 and 4.26 (OR 0.98

While this ratio is generally favorable for significant weight loss, the functional medicine imperative is always on preserving muscle mass

These results suggest that GLP-1R agonists are able to improve cognitive function by attenuating the oxidative stress and mitochondria dysfunction in CNS

The three primary outcome measures were intracranial pressure at 2.5 h, 24 h and 12 weeks and alpha set a priori at less than 0.1